Analyst Research Report Snapshot

Title:

ERYTECH PHARMA - A SOLID GRASP WITH GRASPA

Price:

$10.00

Provider:

Edison Investment Research

Date:

23 Jan 2014

Pages:

12

Type:

AcrobatPDF

Companies referenced:

ERYP.PA RECI.MI TEVA.TA

Available for Immediate Download
Summary:

Erytech is positioned to join the select group of European biotechnology companies with a marketed product. Graspa targets frail and elderly leukaemia patients and is based on the well-established childhood leukaemia treatment L-asparaginase. Top-line pivotal data are anticipated in Q414, which should allow for first European launch in early 2016 with partner Recordati. We value Erytech at €96m, or €17.2/share.

Why buy analyst research?

  • Institutional quality research
  • Available for Immediate Download
  • Detailed company or industry insight
  • Print or save
  • 24 hour customer support
Return to previous page without adding this item to your cart.
Email Customer Support.

About Analyst Research

Analyst research reports are available for immediate download after purchase. You will have unlimited access to the report for 24 hours after purchase, to download, print or save it as many times as you wish. Analyst Research provided by Reuters does not constitute investment advice, and is not endorsed by Reuters Research. This information is protected by copyright and intellectual property laws. More information on Analyst Research.